Wall Street brokerages expect Cognex Co. (NASDAQ:CGNX) to report sales of $227.17 million for the current quarter, according to Zacks. Four analysts have made estimates for Cognex’s earnings. The highest sales estimate is $230.31 million and the lowest is $223.30 million. Cognex posted sales of $259.74 million during the same quarter last year, which would indicate a negative year over year growth rate of 12.5%. The company is expected to announce its next quarterly earnings results on Monday, October 29th.

On average, analysts expect that Cognex will report full-year sales of $810.56 million for the current financial year, with estimates ranging from $803.39 million to $822.53 million. For the next financial year, analysts forecast that the company will report sales of $960.80 million per share, with estimates ranging from $942.97 million to $998.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Cognex.

Cognex (NASDAQ:CGNX) last posted its quarterly earnings results on Monday, July 30th. The scientific and technical instruments company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.02. Cognex had a net margin of 20.57% and a return on equity of 22.95%. The company had revenue of $211.26 million for the quarter, compared to analyst estimates of $204.87 million. During the same quarter in the previous year, the firm posted $0.63 earnings per share. The company’s quarterly revenue was up 18.6% compared to the same quarter last year.

CGNX has been the topic of several research reports. Sanford C. Bernstein raised shares of Cognex from a “market perform” rating to an “outperform” rating and set a $40.10 price target on the stock in a research report on Wednesday, August 1st. They noted that the move was a valuation call. ValuEngine lowered shares of Cognex from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 22nd. Northcoast Research set a $56.00 target price on shares of Cognex and gave the stock a “buy” rating in a report on Tuesday, July 31st. Robert W. Baird reaffirmed a “hold” rating and set a $48.00 target price on shares of Cognex in a report on Tuesday, July 31st. Finally, Zacks Investment Research lowered shares of Cognex from a “hold” rating to a “sell” rating in a report on Thursday, July 26th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $54.79.

In other Cognex news, Director Jerry A. Schneider sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, August 3rd. The shares were sold at an average price of $52.50, for a total value of $131,250.00. Following the completion of the transaction, the director now owns 4,500 shares of the company’s stock, valued at approximately $236,250. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Anthony Sun sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $53.01, for a total transaction of $530,100.00. Following the completion of the transaction, the director now directly owns 284,262 shares of the company’s stock, valued at approximately $15,068,728.62. The disclosure for this sale can be found here. Corporate insiders own 5.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in Cognex by 6.3% in the 2nd quarter. BlackRock Inc. now owns 17,769,276 shares of the scientific and technical instruments company’s stock worth $792,687,000 after buying an additional 1,060,494 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Cognex by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,260,702 shares of the scientific and technical instruments company’s stock worth $368,509,000 after buying an additional 1,124,420 shares in the last quarter. Janus Henderson Group PLC grew its stake in Cognex by 103.1% in the 2nd quarter. Janus Henderson Group PLC now owns 4,797,355 shares of the scientific and technical instruments company’s stock worth $214,025,000 after buying an additional 2,435,314 shares in the last quarter. Eagle Asset Management Inc. grew its stake in Cognex by 41.4% in the 2nd quarter. Eagle Asset Management Inc. now owns 3,345,230 shares of the scientific and technical instruments company’s stock worth $149,230,000 after buying an additional 980,194 shares in the last quarter. Finally, Joho Capital LLC grew its stake in Cognex by 24.1% in the 2nd quarter. Joho Capital LLC now owns 3,069,024 shares of the scientific and technical instruments company’s stock worth $136,909,000 after buying an additional 595,358 shares in the last quarter. 90.28% of the stock is owned by institutional investors and hedge funds.

NASDAQ CGNX opened at $53.37 on Wednesday. Cognex has a 12-month low of $39.90 and a 12-month high of $72.99. The company has a market capitalization of $9.26 billion, a PE ratio of 36.85 and a beta of 1.66.

The company also recently announced a quarterly dividend, which was paid on Friday, August 31st. Investors of record on Friday, August 17th were issued a dividend of $0.045 per share. This represents a $0.18 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date was Thursday, August 16th. Cognex’s dividend payout ratio (DPR) is presently 12.41%.

About Cognex

Cognex Corporation provides machine vision products that capture and analyze visual information in order to automate tasks primarily in manufacturing processes worldwide. The company offers machine vision products, which are used to automate the manufacturing and tracking of discrete items, such as mobile phones, aspirin bottles, and automobile tires by locating, identifying, inspecting, and measuring them during the manufacturing or distribution process.

See Also: How Short Selling Works

Get a free copy of the Zacks research report on Cognex (CGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cognex (NASDAQ:CGNX)

Receive News & Ratings for Cognex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognex and related companies with MarketBeat.com's FREE daily email newsletter.